Test Template Ronny Allan
November 28, 2025
No Comments
Discover more from Ronny Allan – Living with Neuroendocrine Cancer Subscribe to get the latest posts sent to your email. Type your email… Subscribe
Translate
Subscribe to Blog via Email
Join 27.4K other subscribers
Ronny Allan
Ronny Allan is a 3 x award-winning accredited patient leader advocating internationally for Neuroendocrine Cancer and all other cancer patients generally. Check out his Social Media accounts including Facebook, BlueSky, WhatsApp, Instagram and and X.
Updated 24th September 2025.
Introduction
There’s a lot of Immunotherapy stuff out there! The picture regarding its use in Neuroendocrine Neoplasms is not clear and there is no general roadmap printed. I first heard of Immunotherapy for NETs following attendance at ENETS 2017 in Barcelona. The presentation that sticks out was one given by Dr Matthew Kulke, a well-known NET Specialist in Boston. My reaction to the presentation was one of ‘expectation management’ and caution i.e. it’s too soon to know if we will get any success and when we will get it. He also hinted that it’s more likely that any success will first be seen in poorly differentiated high-grade Neuroendocrine Carcinoma (NEC).
If you fast forward to 2025, that prediction worked out and there is little evidence of use in well differentiated NETs.
However …….
However, since then the landscape of different ways of targetting immunotherapy has broadened. Initially, most of the scope involved the use of immune checkpoint inhibitors (see below) but now there are several forms of immunotherapy, some of which I have already written about seperately without consolidating in here until now.
Immune Checkpoint Inhibitors: The mainstream use of immunotherapy is based on this type of targetting. These drugs block proteins that keep the immune system in check, allowing T-cells to attack cancer more effectively. Most of the effort you will see below involves checkpont inhibitors, particularly PD-1, PD-L1, CTLA-4, LAG-3.
Monoclonal Antibodies (MABs): These are man-made antibodies that can identify and bind to specific cancer cells, flagging them for destruction by the immune system. It’s complicated but there are Immune-Targeting MABs and tumour targeting MABs. i.e. they can be a type of targeted cancer drug or immunotherapy ….. but they can work in both ways. e.g. Drugs such as pembrolizumab (targeting PD-1/PD-L1) can be used with a MAB called Avelumab. Monoclonal antibodies are often used in combination with other cancer treatments like chemotherapy, radiation, or other forms of immunotherapy – so these are very versatile drugs.
CAR T-cell Therapy: This involves genetically modifying a patient’s own T-cells to recognize and kill cancer cells. Read about CAR-T and NENs click here.
Cancer Vaccines: These are used to stimulate an immune response against cancer cells. Read one example of cancer vaccines and NENs click here
Cytokines: These are proteins that help regulate the immune system. They were once used many years ago on NETs but sparingly today due to the introduction of more targeted treatments such as somatostatin analogues and somatostatin receptor based treatments. Left here for completeness. One example in the annals of NET oncology is Interferon alpha (IFN-a).
Neuroendocrine Tumours – “an immunological desert”
Not my words, they’re those of a well known NET specialist. It’s true that while there have been some approvals in two Neuroendocrine Carcinomas (the more esoteric ones), there’s little evidence immunotherapy is effective in all Neuroendocrine Carcinomas or the slower growing well differentiated NETs.
This study from Southampton UK Researchers discovered a “cold environment” in a form of cancer which hides it from the immune system. Neil Pearce, co-founder of PLANETS and a consultant hepatobiliary surgeon (my surgeon!), said: “This is extremely useful research which shows that NETs have some yet to be identified mechanism which currently prevents immune cells from recognising them. “It could be a discovery that leads us to trying to find ways to switch on the immune system in different ways to recognise tumour cells.”
Read more here
Immunotherapy in Neuroendocrine Neoplasms: A Diamond to Cut
Immunotherapy – Hype or Hope?
Retain hope but just be cautious with some of the hype surrounding Immunotherapy
Immunotherapy is exciting, there is no foubt about that when you read about the lastest batch of drugs in clinical trials and the use of combo drugs. The new kids on the block for NENs, DLL-3 is being watched carefully. Their use with small cell lung cancer (technically a Neuroendocrine Carcinoma) has led to wider clinical trials for extra pulmonary NENs (epNENs) particularly those known to express DLL-3 in higher than average levels. See DLL-3 section below.
We also need to be aware of the risks of taking the brakes off the immune systems. We have seen and heard more and more stories about people with grim cancer diagnoses who became cancer-free after treatment with immunotherapy. This offers hope to those with cancer, but we need to be cautious when discussing immunotherapy. This treatment method is still realtively new, and the cancer community is still learning about how it affects the body. An unfettered immune system may end up attacking healthy, functioning parts of a person’s body (a blue n blue scenario), causing unpredictable side effects that may be life-threatening EVEN if not treated early. Hopefully the newer types of immunotherapy are considereing safety now that more is known.
Existing Blog follows
I wanted to leave on my research below, most is up to date but let me know if you think it is not!
Approvals for Neuroendocrine Neoplasms?
This drug crops up everywhere and it has connections to many different cancers. Before I talk about this trial called PLANET (see well-differentiated tumours section below), it’s very useful to take a quick look at the history of Keytruda which was only really made famous after former US President Jimmy Carter was treated with it for metastatic melanoma. There was a lot of media hype surrounding what made his treatment successful as he was also given radiation for his brain tumours and his large liver tumour was removed by surgery. However, putting the hype and conjecture to one side, Keytruda’s CV is pretty impressive. Pembrolizumab (Keytruda) is currently approved to treat certain scenarios in Hodgkin lymphoma, Melanoma, Non-small cell lung cancer (NSCLC), Squamous cell carcinoma of the head and neck, Urothelial carcinoma, Microsatellite instability-high (MSI-H) related cancers (a very interesting development as it’s the US FDA’s very first approval on a tissue/site agnostic basis).
However, despite this excellent record, it’s worth also noting that NANETS 2018 reported limited use of Keytruda (see below) as a single agent to treat high grade Neuroendocrine Neoplasms. Other approvals are anticipated.
In March 2023, the FDA has approved pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. Read more – click here.
In June 2020, the FDA has approved pembrolizumab (Keytruda) to treat adult and pediatric patients with unresectable or metastatic solid tumors that are tissue tumor mutational burden (TMB) –high (≥10 mutations/megabase) and have progressed following prior therapy and who have no satisfactory alternative treatment options. The approval is based in part on the phase 2 KEYNOTE-158 trial, in which a link was established between TMB-high status and improved overall response rate (ORR) with the PD-1 inhibitor in patients with various solid tumors. The multicenter, multicohort, nonrandomized, open-label KEYNOTE-158 trial accrued patients with anal, biliary, cervical, endometrial, salivary, thyroid, or vulvar carcinoma, mesothelioma, a neuroendocrine tumor, or small cell lung cancer. Patients had to have an ECOG performance status of 0 or 1 and have progressed on or be intolerant to at least 1 prior line of standard treatment. The investigators used the FoundationOne CDx™ assay to assess TMB in FFPE tumor samples, with 10 Mut/Mb used as the threshold for TMB-high status.
On March 18, 2019, the FDA approved Atezolizumab (TECENTRIQ) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). Click here.
In Dec 2018, US FDA approved pembrolizumab for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). Click here.
In Aug 2018, the FDA granted Nivolumab (OPDIVO) accelerated approval for third-line treatment of metastatic small cell lung cancer (SCLC) (a type of Neuroendocrine Carcinoma). Read more – click here.
In March 2017, FDA granted accelerated approval to Avelumab (BAVENCIO) for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma (MCC). MCC is a Neuroendocrine Carcinoma of the skin. Avelumab is a programmed death-ligand 1 (PD-L1) blocking human IgG1 lambda monoclonal antibody. This is the first FDA-approved product to treat this type of cancer – Click here for more information.
Clinical Trials for Neuroendocrine Carcinoma (poorly differentiated)
- Completed – Pembrolizumab (Keytruda) for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma (Pembro NEC)
- Completed – A Study of Pembrolizumab (Keytruda) in Patients With Neuroendocrine Tumors
- Completed – Pembrolizumab (Keytruda) – based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
- This trial is interesting. Nivolumab (Opdiva) and Ipilimumab (Yervoy) in Treating Patients With High Grade Neuroendocrine Carcinoma and other cancers. It’s a multiple cancer setup and includes several of the less common NET/NEC types including ‘Lung Carcinoid’, ‘Anal NEC’, ‘Gastric NEC’, ‘Pancreatic NEC’ ‘Esophageal NEC. Looking at the list in the trial document, I’m thinking they might mean high-grade Lung Neuroendocrine rather than ‘carcinoid’. I could be wrong. Active, not recruiting as completes October 2023. Update from 2019 AACR Annual Meeting. The immune checkpoint inhibitor combination of nivolumab (Opdivo) and ipilimumab (Yervoy) induced a greater than 40% response rate and was well tolerated in patients with high-grade neuroendocrine carcinoma, according to findings from the phase II DART trial presented at the 2019 AACR Annual Meeting. “DART is the first NCI-funded rare tumor immunotherapy basket study which we think is unique in its design scale,” lead author Sandip Patel MD, an associate professor of medicine at the University of California San Diego School of Medicine, said in a press briefing at the meeting. “We’re studying over 37 rare tumor types [using the] combination of ipilimumab plus nivolumab. The neuroendocrine cohort, the nonpancreatic cohort, had promising signs of benefit—[particularly] in patients with high-grade neuroendocrine carcinoma—independent to primary site,” added Patel.
See clinical trial document NCT02834013
See announcement of trial data – click here See also a French trial entitled “Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC)” Clinical Trial reference NCT03591731 – Active, not recruiting
UPDATE from NANETS 2018. “A preliminary trial of checkpoint blockade for neuroendocrine tumors (NETs) produced little evidence of activity, according to data reported here. Only one of 21 patients with high-grade NETs responded to treatment with pembrolizumab (Keytruda). Three others had stable disease. The trial had an objective response threshold of 5% as the definition of clinically interesting, as reported at the North American Neuroendocrine Tumor Society annual symposium. “Pembrolizumab, though generally well tolerated, showed limited activity as a single agent in high-grade neuroendocrine neoplasms (NENs) in this study,” Arvind Dasari, MD, of MD Anderson Cancer Center in Houston, and colleagues concluded.” More info.
SPARTALIZUMAB (PDR001)
This is an interesting trial sponsored by Novartis (of Octreotide and Lutathera fame). PDR001 (anti-PD-1) is an investigational immunotherapy being developed by Novartis to treat both solid tumors and lymphomas (cancers of the blood). It is currently being trialed on many cancers including Neuroendocrine Neoplasms both well and poorly differentiated. Click here: Clinical Trial SPARTALIZUMAB – Immunotherapy for Neuroendocrine Neoplasms (PDR001)
Trial Completed. “Single agent PD-1/PD-L1 inhibitors have not demonstrated clinical utility in an unselected NET population and should not be used outside of clinical trials. The potential for PD-L1 inhibition in the thoracic cohort warrants further investigation”
Clinical Trials for Neuroendocrine Tumours (well differentiated)
I found the following:
New blog post on 21 July 2022 – Atezolizumab and Bevacizumab in Solid Tumors
Click here or on the photo
Pembrolizumab (Keytruda) in combination with Lanreotide – trial complete June 7, 2022
According to the trial documentation, it’s for patients with non-resectable, recurrent, or metastatic well or moderately (sic) differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). i.e. most of us. You can read about the PLANET trial by clicking here or on the photo below. Trial complete Jun 2022, nothing concrete to report yet.
“Further studies to identify other approaches to increase the immunogenicity of well/moderately differentiated GEP-NETs are required,” concluded the investigators.
PDR001 (Spartalizamab) – a Novartis drug
Read about this trial click here. “The potential for PD-L1 inhibition in the thoracic cohort warrants further investigation.”
Study of Pembrolizumab in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28) – NCT03054806 and another called ‘A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors’ (KEYNOTE 158) NCT02628067 – Update from Gastrointestinal Tumor symposium 2019.
“Disappointing results for single agent pembrolizumab (Keytruda) in well differentiated NET. Response Rate 3.7%. Not a viable option”. Listen to Dr Jonathan Strosberg describe the poor results. Click here
Targeted Drugs vs Immunotherapy
In 2025, the lines are becoming blurred! A couple of examples here.
DLL-3 – Why DLL3 Therapies can be considered Immunotherapy
DLL3-targeted agents like Tarlatamab are considered immunotherapy because they engage the immune system directly:
• BiTEs (Bispecific T-cell Engagers): These link DLL3 on tumor cells to CD3 on T cells, forcing T cells to recognize and kill DLL3-expressing cells. That’s a classic immune-mediated cytotoxic mechanism.
• CAR-T cells: These are genetically engineered T cells that recognize DLL3 and destroy tumor cells—again, a direct immune response.
Even though DLL3 is a molecular target (like mTOR or VEGFR), the mode of action is immunologic, not just inhibitory. That’s why it can be classified under immunotherapy.
What About ADCs Like Rova-T?
Antibody-drug conjugates (ADCs) blur the lines even more. For example ADCs and DLKL-3 drugs can be used as a mono treatment. e.g. Rova-T targets DLL3 but delivers a cytotoxic payload—so it’s more of a targeted cytotoxic therapy than immunotherapy per se. However, because it uses an antibody to recognize a tumor antigen, it’s often grouped under immune-targeted therapies, especially in regulatory and clinical trial contexts.
DLL-3 for Neuroendocrine Neoplasms (NENs)
I wrote an entire blog about DLL-3 and how they are expressed, offering targets in NENs. Read that by clicking here or on the graphic below.
General Clinical Trials Disclaimer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact. If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net
The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.
Subscribe to Blog via Email
Join 27.4K other subscribers
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
Blog Facebook. Like this page please.
Personal Facebook. Like this page please.
Awareness Facebook Like this page please.
Follow me on X (formerly twitter)
Check out my online presentations
Check out my WEGO Health Awards
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Facebook
X
Pinterest
WhatsApp
Email
Bone metastases in Neuroendocrine Tumours (NET)
November 17, 2025
No Comments
Bone metastases in Neuroendocrine Tumours (NET) Many of you will know that I am a stage IV small intestine NET and I have one bone
MP0712 (212Pb x DLL3), Radio-DARPin – DLL3 Radioligand Therapy Trial for Neuroendocrine Neoplasms
November 16, 2025
No Comments
What is Radioligand Therapy? When you browse the internet, you may see the term “Radioligand Therapy (RLT)” and wondered what it was. There’s a simple
Piss off Cancer, it’s been 15 years since my “big surgery”
November 9, 2025
No Comments
D Day I was 54 years and 9 months old at diagnosis on 26th July 2010. For the first few months, I had no idea
The Dethroning of Neuroendocrine Neoplasms as an Orphan Disease: US Incidence, Prevalence, and Survival in the 21st Century
November 8, 2025
No Comments
USA – Prevalence of Neuroendocrine Neoplasms (NENs) breaches the Orphan Disease threshold for the first time (officially) The latest US SEER figures confirm that staggering
Reframing Neuroendocrine Neoplasms Beyond “Rare”
November 7, 2025
No Comments
Reframing Neuroendocrine Neoplasms: Beyond “Rare” Neuroendocrine neoplasms (NENs) have outgrown the “rare disease” label. e.g. Across the U.S., UK, and Australia, they now rank among
Every stripe is lost awareness
November 6, 2025
No Comments
Sincer 2015, my message has not changed. My message continues to be justified because since then, many important voices in the NEN community have repeated
Ronny Allan – a review of my blog activity September and October 2025
November 1, 2025
No Comments
Here is the monthly summary of September and October 2025 on RonnyAllan.NET – Every share helps someone understand or even work towards a diagnosis,
Neuroendocrine Cancer? – Where to find a NET Centre/Specialist Worldwide
October 31, 2025
15 Comments
Scroll down to check out the doctors list just below Scroll down to also see information on “NET Aware” Dietitians. Important note The accuracy of
Disclaimer
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional. Some content may be generated by AI which can sometimes be misinterpreted. Please check any references attached.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Buy me a cup of tea or two
Buy me a cup of tea or two? Change the number below to increment. i.e insert 2 = £8, 3 = £12, etc
Overheads to run this site, e.g. software packages, domain registration fees, software tools, misc items. Donate £4 or more so I have the fuel to keep on providing great content!
£4.00
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
Discover more from Ronny Allan - Living with Neuroendocrine Cancer
Subscribe to get the latest posts sent to your email.